The triple-agonist hypothesis predicts that GIP receptor activation, by enhancing insulin secretion and improving glycemic control, will offset the hyperglycemic effects of glucagon receptor activation while preserving its energy-expenditure benefits
it lacked any of the acidity youd expect from a citrus flavor and allowed some of the medications bitterness to sneak through, but it wasnt unpleasant for a medication
Though data is still emerging, it appears that GLP-1 RAs show promise as a potential adjunct medication for IIH patients with benefits that extend beyond weight loss
If your clinician finds thyroid dysfunction, insulin resistance, or chronic inflammation driving your weight gain, we address those alongside GLP-1 therapy
Mochi, Eden, and Shed allow the switch in-platform
To put the numbers into context, the incidence of medullary thyroid cancer in the United States is approximately 600 cases per year